A Phase 1 interventional study of SHR-2004 injection in Atrial Fibrillation, sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Completed at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 376 studies in Atrial Fibrillation with a site in China — 161 open to participants now, 182 under way, 4 of them phase 3. Atrial Fibrillation · China.
Among the 376 studies in Atrial Fibrillation with a site in China, this one is the 251st largest by enrollment of the 255 interventional ones that give a count, is one of 45 that started in 2024, is one of 3 in phase 1, and was the 220th registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 960 are open to participants now.
Browse Atrial Fibrillation studies →161 of the 376 studies in Atrial Fibrillation with a site in China are open now. Recruiting first, the newest first:
Biosense Webster, Inc. · Sites in China
Ages 18–80
Johnson & Johnson Medical (Shanghai) Ltd. · Sites in China
Ages 18–80
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Peking Union Medical College Hospital · Sites in China
Ages 60+
Jiangsu Taizhou People's Hospital · Sites in China
Ages 65–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
376 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 20 · Phase 4 28
First in 2005; this study’s year is marked. 45 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 150 across 2,476 interventional studies indexed under Atrial Fibrillation.
Median enrollment 234 across the 255 interventional studies, 500 across the 121 observational. Of the 110 that completed or were terminated, 24 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
71 of 376 have an industry lead sponsor. The 10 most frequent:
This study is registered under Beijing Suncadia Pharmaceuticals Co., Ltd, one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Beijing Suncadia Pharmaceuticals Co., Ltd is the lead sponsor of 25 studies on the registry; 9 are open to participants now.
Jiangsu HengRui Medicine Co., Ltd. has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
50 of the studies in Atrial Fibrillation with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT06722196Phase 3Jilin Heart HospitalBiodEgradable Soaked Amiodarone paTch Use for the Prevention of Atrial Fibrillation After Cardiac Surgery | 2027-01-15 |
| NCT06125925The First Affiliated Hospital with Nanjing Medical UniversityCatheter Ablation in Atrial Fibrillation Patients With HFpEF (STABLE-SR IV Trial) | 2026-11 |
| NCT07139314Capital Medical UniversityTiming of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2 | 2026-11-30 |
| NCT07541339Beijing Anzhen HospitalSafety and Efficacy of Conscious Sedation Versus General Anesthesia in Pulsed-Field Ablation for Paroxysmal Atrial Fibrillation | 2026-12-01 |
Add all 50 to your calendar (.ics) → With an account.
Among the 376 studies in Atrial Fibrillation with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is an open-label Phase Ib clinical study with the primary objective of evaluating the safety and tolerability of multiple subcutaneous injections of SHR-2004 injection in patients with atrial fibrillation, and the secondary objective is to evaluate its pharmacokinetic (PK), pharmacodynamic (PD) and immunogenicity characteristics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SHR-2004 injection
dose 1 or dose 2 or dose 3 or dose 4 or dose 5 or dose 6
Incidence and severity of adverse events (including bleeding events)
Time frame: Up to 136 Days
Pharmacokinetics of SHR2004: Peak Plasma Concentration (Cmax)
Time frame: Up to 136 Days
Pharmacokinetics of SHR2004: Area under the plasma concentration versus time curve (AUC)
Time frame: Up to 136 Days
Pharmacokinetics of Dupilumab: Elimination half life (t1/2)
Time frame: Up to 136 Days
PD endpoint: absolute and relative change values of coagulation factor XI (FXI) activity
Time frame: Up to 136 Days
PD endpoint: absolute and relative change values of activated partial thromboplastin time (APTT)
Time frame: Up to 136 Days
Immunogenicity endpoint: the incidence and timing of ADA positivity in SHR-2004
Time frame: Up to 136 Days
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Apr 2024 to primary completion in Jan 2025, 9 months.
Of 20 phase 1 interventional studies under Atrial Fibrillation, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's 9 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SHR-2004
Beijing Suncadia Pharmaceuticals Co., Ltd →